Novel treatment of chronic graft-versus-host disease in mice using the ER stress reducer 4-phenylbutyric acid

Shin Mukai
Keio University School of Medicine

Yoko Ogawa
Keio University School of Medicine

Fumihiko Urano
Washington University School of Medicine

Chie Kudo-Saito
Keio University School of Medicine

Yutaka Kawakami
Keio University School of Medicine

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/5577

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid

Shin Mukai, Yoko Ogawa, Fumihiko Urano, Chie Kudo-Saito, Yutaka Kawakami & Kazuo Tsubota

Chronic graft-versus-host disease (cGVHD) is a notorious complication of allogeneic hematopoietic stem cell transplantation and causes disabling systemic inflammation and fibrosis. In this novel study, we focused on a relationship between endoplasmic reticulum (ER) stress and cGVHD, and aimed to create effective treatment of cGVHD. A series of experiments were conducted using a mouse model of cGVHD. Our data suggested (1) that ER stress was elevated in organs affected by cGVHD and (2) that 4-phenylbutyric acid (PBA) could reduce cGVHD-induced ER stress and thereby alleviate systemic inflammation and fibrosis. Because fibroblasts are thought to be implicated in cGVHD-elicited fibrosis and because macrophages are reported to play a role in the development of cGVHD, we investigated cGVHD-triggered ER stress in fibroblasts and macrophages. Our investigation demonstrated (1) that indicators for ER stress and activation markers for fibroblasts were elevated in cGVHD-affected lacrimal gland fibroblasts and (2) that they could be reduced by PBA. Our work also indicated that splenic macrophages from PBA-dosed mice exhibited the lower levels of ER stress and M2 macrophage markers than those from cGVHD-affected mice. Collectively, this study suggests that the reduction of ER stress utilizing PBA can be a clinically translatable method to treat systemic cGVHD.
When proteins are synthesized in the ER, they need to be folded adequately and ER chaperones assist the protein folding15. However, hypoxia, calcium ion depletion, oxidative injury, viral infections and inflammatory cytokines prevent the ER from performing its normal protein folding19,20. When unfolded and misfolded proteins are accumulated in the ER, it causes ER stress and the following three transmembrane proteins are consequently activated to initiate the unfolded protein response (UPR): inositol requiring (IRE) 1α, PKR-like ER kinase (PERK) and activating transcription factor (ATF) 6α18. However, if the UPR is prolonged or unsuccessful, inflammatory and apoptotic pathways are activated18. Hence, the unsuccessful UPR leads to the expression of (1) the proinflammatory molecules thioredoxin interaction protein (TXNIP) and transcription factor nuclear factor (CHOP)21–26. 

In this study, we aimed to devise effective treatment of cGVHD. Based on the previous findings, we envisaged (1) that ER stress would be increased in cGVHD-impaired organs and (2) that mitigation of ER stress could be effective treatment of cGVHD. To achieve this goal, we used 4-phenylbutyric acid (PBA) as an ER stress reducer27. (Supplementary Figure 1A) PBA is commercially available and can be an inexpensive starting material in organic synthesis18. In clinical settings, PBA is approved by FDA and has been utilized to cure urea cycle disorders27. Furthermore, several articles demonstrate that PBA can be effective for chronic inflammation and age-related diseases such as type 2 diabetes and obesity-caused chronic inflammation through mitigation of ER stress18,28,29. Hence, it was envisioned that PBA could be a safe and efficacious drug for cGVHD, in which systemic inflammation and fibrosis are highly problematic. Herein, we report the world-first strategy to treat cGVHD using the ER stress reducer PBA.

**Results**

**Elevation of ER stress markers in cGVHD-affected organs.** The initial venture toward our overarching aim was to investigate whether ER stress was elevated in cGVHD-affected organs by measuring ER stress markers. Real-time quantitative PCR (qPCR) and immunoblot analysis suggested (1) that the ER stress indicators GRP78, CHOP, p-PERK, p-eIF2α, and p-IRE1α were increased in murine organs affected by cGVHD compared with control subjects and (2) that accordingly the following two inflammatory molecules were activated and/or augmented in the cGVHD-impaired organs: NF-κB and TXNIP (Fig. 1A–C). As evidenced by electron micrographs, in cGVHD-impaired lacrimal gland epithelia, accumulated misfolded/unfolded proteins caused the ER to expand (Fig. 1D). Conversely, the ER in the controls seemed intact (Fig. 1D). These observations are indicative of the elevation of ER stress in cGVHD-affected organs.

**Deactivation of the ER stress-induced inflammatory pathways utilizing PBA.** Once we found that ER stress was increased in the organs impaired by cGVHD, our next attempt was to treat cGVHD through reduction of ER stress by the use of PBA. As depicted in the Methods section, we administered PBA or the solvent-vehicle to mice which underwent allogeneic BMT. Immunoblot analysis indicated that organs collected from the PBA-treated mice exhibited the lower protein levels of GRP78, CHOP, p-PERK, p-eIF2α, and p-IRE1α compared with those from the vehicle-treated mice (Fig. 2A,B; Supplementary Figure 2A,B). Consequently, the associated proinflammatory molecules NF-κB and TXNIP were subdued in the organs treated with PBA compared to their vehicle-treated counterparts (Fig. 2A,B; Supplementary Figure 2A,B).

**Histological observations of cGVHD target organs.** HE and Mallory pictures of cGVHD-susceptible organs indicate that the reduction of ER stress using PBA can be efficacious treatment of cGVHD (Fig. 3). As judged by the HE pictures, inflammatory cell infiltration was repressed in the PBA-medicated organs compared with their vehicle-mediated counterparts (Fig. 3A; Supplementary Figure 3A). Particularly, (1) the intestinal villi of the PBA-treated small and large intestines seemed intact in contrast to those treated with the solvent-vehicle, (2) the vehicle-treated skin was thickened, lost the fatty tissues and had the elevated density of collagen bundles by contrast with the PBA-treated skin, (3) meibomian glands in the vehicle-mediated eyes were decreased and shrunk compared with their PBA-mediated counterparts and (4) the thinning and damage in vehicle-injected conjunctival epithelia were observed in contrast to their PBA-injected counterparts, which suggested that a symblepharon could be prevented by systemic injection of PBA (Fig. 3A, Supplementary Figure 3A). As indicated by the immunostaining and subsequent counting of CD45+ cells, the number of inflammatory cells in the PBA-treated organs was considerably lower than that in their vehicle-treated counterparts (Fig. 3B,E; Supplementary Figure 3B,D). These observations are also indicative of the suppression of immune cell migration and proliferation in the PBA-treated organs. Furthermore, systemic fibrosis is one of the most serious problems in cGVHD31. Mallory’s staining revealed that cGVHD-induced fibrosis was substantially subdued in the PBA-medicated organs compared with the vehicle-medicated ones (Fig. 3C; Supplementary Figure 3C). Electron micrographs of the lacrimal glands indicate that in the case where the lacrimal glands were treated with the solvent-vehicle, (1) the ER of the epithelial and endothelial cells were expanded due to the accumulation of unfolded/misfolded proteins, (2) there was a large amount of cell debris in the stroma and (3) mitochondria in the epithelial and endothelial cells were damaged (Fig. 3D). Electron micrographic analysis of the small intestine also demonstrated that when the small intestine was treated with the solvent-vehicle, its villi were demolished and the neighboring tissues were damaged (Fig. 3D). These histological findings were not observed in the PBA-treated lacrimal glands or small intestine. In addition, PAS staining revealed (1) that goblet cells in the PBA-injected small intestine and conjunctival epithelia outnumbered those in their vehicle-injected counterparts and (2) that the structures of intestinal and conjunctival mucosal membranes were retained by systemic injection of PBA (Supplementary Figure 4A,B). As judged by all the histological observations, PBA can alleviate systemic inflammation and fibrosis elicited by cGVHD-related ER stress.
Figure 1. ER stress markers in cGVHD target organs. (A) qPCR analysis of GRP78 in cGVHD-affected organs (red) and control subjects (blue). Data from one of two similar experiments are shown. The data are presented as means, ±SD, Control: n = 5, cGVHD: n = 4–5 *P < 0.05. (B) Immunoblot analysis of ER stress indicators and the associated inflammatory molecules was carried out. (Lanes 1, 3, 5, 7: Syngeneic control subjects, Lanes 2, 4, 6, 8: cGVHD-impaired organs) Cropped blots are displayed. (C) The corresponding quantitative analysis of the protein bands was conducted. cGVHD-affected organs (red) and control subjects (blue). Data from one of two similar experiments are shown. The data are presented as means, ±SD, Control: n = 4, cGVHD: n = 4 *P < 0.05. (D) Electron micrographs of epithelial cells in the cGVHD-affected lacrimal gland and those in its syngeneic control counterpart. The pictures were taken at 2000x magnification, and the scale bar is 5 μm. In the image of cGVHD-affected lacrimal gland epithelia, asterisks are placed where the ER was expanded due to the accumulation of proteins.
Figure 2. Suppression of cGVHD-caused ER stress by PBA. (A) Immunoblot assays were performed to examine the protein levels of ER stress markers and the associated inflammatory molecules in the cGVHD target organs. (Lanes 1, 3, 5, 7: PBA-medicated organs. Lanes 2, 4, 6, 8: Vehicle-medicated organs) Cropped blots are displayed. (B) The target proteins in each organ were subsequently quantified by densitometry. PBA-treated organs (blue) and vehicle-treated organs (red). Data from one of two similar experiments are shown. The data are presented as means, ±SD, PBA: n = 4, Vehicle: n = 4, *P < 0.05.
Reduction of inflammatory and pro-fibrotic mediators by the use of PBA.

To examine more closely whether PBA could mitigate cGVHD-caused systemic inflammation, ELISA was conducted to measure the levels of the inflammatory molecules MCP-1, TNF-α and IFN-γ in sera collected from the PBA- and vehicle-injected mice. The sera from the PBA-medicated mice exhibited the lower protein levels of MCP-1, TNF-α and IFN-γ in comparison to those from their vehicle-mediated counterparts. (Figure 4A) Moreover, we performed more meticulous investigation into the alleviation of cGVHD-triggered systemic fibrosis, and immunoblot analysis revealed that the pro-fibrotic mediator connective tissue growth factor (CTGF) was overexpressed in the vehicle-treated organs, yet it was not observed in those treated with PBA (Fig. 4B,C; Supplementary Figure 5A,B). These data support that PBA can repress cGVHD-induced ER stress and consequently mitigate systemic inflammation and fibrosis.

Correlation between ER stress and dysfunctional fibroblasts.

Systemic fibrosis arising from cGVHD is a serious problem and causes multiple organ failure31. Although the mechanisms of cGVHD-triggered
fibrosis still need to be elucidated, fibroblasts are conceivably implicated in the development of fibrosis. Several biological signals stimulate fibroblasts so that they can play an integral role in several biological processes such as wound healing. However, if fibroblasts are activated in an uncontrolled manner, they produce abnormal collagen bundles and thereby induce severe fibrosis although there is little information about what causes their abnormality. Hence, we strived to unravel a relationship between cGVHD-elicited ER stress and dysfunctional fibroblasts. To accomplish this goal, we cultured fibroblasts from the PBA- and vehicle-treated murine lacrimal glands as described in the Methods section. As confirmed by immunoblot assays, the cultured lacrimal gland fibroblasts (expressing α-SMA) were not contaminated with epithelial cells (cytokeratin positive cells) (Supplementary Figure 13), and the following experiments were carried out by the use of sufficiently pure fibroblasts. Immunoblot analysis of the cultured fibroblasts suggested that GRP78, CHOP, phosphorylated PERK, phosphorylated eIF2α, and phosphorylated IRE1α were greatly suppressed by treatment of the mice with PBA in comparison to the solvent-vehicle (Fig. 5A). Accordingly, (1) the protein levels of HSP47 and CTGF, markers for fibroblast activation and fibrosis, respectively, (2) the production of MCP-1 and (3) the mRNA level of IL-6 were reduced in the PBA-treated fibroblasts compared with their vehicle-treated counterparts (Fig. 5A–D).
Link between ER stress and the polarization of macrophages. Macrophages serve a crucial role in immune responses and inflammation, and an earlier article indicates that senescent macrophages are detrimentally linked with the pathogenic process of cGVHD. Hence, we scrutinized a relationship between cGVHD-induced ER stress and malfunctioning macrophages. In the first instance, immunostaining was conducted to investigate whether macrophages in the murine lacrimal glands expressed the ER stress indicator CHOP. As judged by fluorescence images of the lacrimal glands, when mice were medicated with the solvent-vehicle, macrophages expressing CHOP migrated to the tissues (Fig. 6A). In contrast, no such macrophages were observed in the lacrimal glands collected from the PBA-medicated mice (Fig. 6A). Our subsequent endeavors were to gain greater insights into ER stress in cGVHD-affected macrophages. Toward this end, we cultured splenic macrophages from PBA- and vehicle-injected mice as depicted in the Methods section. As evidenced by immunoblot analysis, the induced macrophages (expressing CD68) were not adulterated with T-cells (CD3+ cells) or B-cells (CD19+ and/or CD20+ cells) (Supplementary Figure 14), and the following results were gleaned utilizing highly pure macrophages. Immunohistochemistry revealed that the vehicle-medicated splenic macrophages expressed CHOP in contrast to the PBA-medicated ones (Fig. 6B). Immunoblot analysis of the macrophages also indicated that in the case where they were treated with PBA, the ER stress markers GRP78, CHOP, phosphorylated PERK, phosphorylated eIF2α, and phosphorylated IRE1α were substantially repressed compared with the solvent-vehicle (Fig. 6C,D). We then conducted qPCR to examine the gene expression of (1)
the M1 macrophage markers IL-1β, IL-6 and MCP-1 and (2) the M2 macrophage markers TGF-β and IL-10 in the splenic macrophages\(^{37}\). As demonstrated by the data, the mRNA expression of TGF-β and IL-10 was increased in the vehicle-treated macrophages in comparison to the PBA-treated ones (Fig. 6E). Conversely, when macrophages were treated with PBA, they showed the higher gene expression of IL-1β and IL-6 than those treated with the solvent-vehicle (Fig. 6E). These outcomes are indicative of the connection between cGVHD-elicited ER stress in macrophages and their differentiation into an alternatively activated phenotype.

**Discussion**
cGVHD is a major complication following HSCT and can be deadly for some patients. Although cGVHD has been studied intensively over the last decades, sluggish progress in developing efficacious treatment of cGVHD
has been made. Patients with cGVHD have been treated with immunosuppressants such as cyclosporine in many cases, however the desired results have been elusive. Hence, clinical settings are in desperate need of effective methods to cure cGVHD. A survey of literature suggests (1) that cellular senescence in donor immune cells and recipient cells detrimentally contributes to the pathogenic process of cGVHD14 and (2) that ER stress serves a detrimental role in the development of chronic inflammation and age-associated diseases29,30. These reports have led us to a new hypothesis (1) that cGVHD-affected organs show the elevated level of ER stress and (2) that alleviation of ER stress can be a robust strategy to ease severe symptoms caused by systemic cGVHD (Fig. 7).

In this proof-of-concept research, cGVHD was experimentally induced in mice. We investigated the pathogenesis of chronic GVHD in the human lacrimal glands from 2001 to 200932,38–41. Our investigation demonstrated that the pathogenesis of lacrimal gland cGVHD in this murine model was reminiscent of that in patients with chronic GVHD1,14,31,42. Excessive inflammation and fibrosis observed in this mouse model greatly resemble those seen in human samples. Furthermore, our previous reports showed that systemic inflammation and fibrosis were observed in this mouse model1,31. Hence, we chose this animal model to tackle systemic cGVHD.

Toward the ultimate goal, we initially elucidated (1) the elevation of ER stress and (2) the increased activity and/or expression of its corresponding proinflammatory molecules such as NF-κB and TXNIP in cGVHD-affected organs. Drobyski and co-workers have demonstrated that NF-κB detrimentally correlates with the pathogenic process of aGVHD and that inhibition of NF-κB can alleviate aGVHD5. Our study suggests that NF-κB is activated in cGVHD-affected organs and that it results partly from unresolved ER stress caused by cGVHD.

With respect to the involvement of TXNIP in the pathogenesis of cGVHD, there is no literature precedent which mentioned an association between TXNIP and cGVHD. Our survey of previous articles has revealed (1) that TXNIP is generated in the downstream of the PERK and IRE1α pathways, (2) that it serves a pivotal role in a crossroad where cells subjected to ER stress determine whether to restore homeostasis or undergo apoptosis and (3) that it induces extensive inflammation by activating the inflammasome nod-like receptor family, pyrin domain containing 3 (NLRP3)22–24. Thus, our investigation indicates that the ER stress-elicited expression of TXNIP can correlate with disabling symptoms of cGVHD.

We obtained these scientifically and medically important outcomes, and our subsequent endeavors were to develop effective therapeutics to treat cGVHD through mitigation of ER stress. We initially attempted to reduce cGVHD-induced ER stress utilizing the ER stress mitigator rapamycin4,43–45 (Supplementary Figure 1B) and found that it could ease ER stress and be efficacious for systemic cGVHD (data not shown). However, it also acts as an immunosuppressive drug and has been reported to induce extensive side-effects such as viral and fungal infections in clinical settings36,47. These reports prompted us to circumvent the setbacks and search for a safer compound to mitigate ER stress, and we chose 4-phenylbutyric acid (PBA), which is a commercially available aromatic fatty acid and can be used as an affordable starting material in synthetic organic chemistry48,49. In medical practice, PBA has been proven to be sufficiently safe to treat urea cycle disorders27. Literature precedent suggests that PBA can attenuate ER stress, since it serves as a chemical chaperone and assists the ER in dealing with unfolded/misfolded proteins50. As demonstrated by previous reports, PBA can be effective for type 2 diabetes
and obesity-elicited chronic inflammation in adipose tissues by lowering ER stress29,30. Taken together, it was envisioned that PBA could be a safe and powerful tool to reduce cGVHD-caused ER stress.

A series of our experiments demonstrated that cGVHD-caused ER stress in murine organs could be mitigated by PBA and that accordingly the ER stress-associated proinflammatory molecules NF-κB and TXNIP were greatly subdued.

With these encouraging results, we subsequently investigate the state of cGVHD-vulnerable organs. Histological, immunohistochemical and electron microscopic analysis of these tissues was conducted. The HE pictures and immunofluorescence images of the cGVHD target organs demonstrated that the PBA-medicated tissues were less inflamed than the vehicle-mediated ones. Our survey of previous reports shows (1) that PBA can alleviate inflammation by reducing ER stress in endothelial cells and (2) that when ER stress is elevated, mitochondria are damaged51–53. As demonstrated by electron micrographs of the lacrimal glands, when mice were treated with the solvent-vehicle, mitochondria in the blood vessels were impaired. In contrast, this phenomenon was not observed in the lacrimal glands collected from the PBA-medicated mice. Thus, these findings indicate that PBA can protect blood vessels from cGVHD-caused ER stress and thereby suppress immune cell migration to tissues.

With these encouraging results, we subsequently investigate the state of cGVHD-vulnerable organs. Histological, immunohistochemical and electron microscopic analysis of these tissues was conducted. The HE pictures and immunofluorescence images of the cGVHD target organs demonstrated that the PBA-medicated tissues were less inflamed than the vehicle-mediated ones. Our survey of previous reports shows (1) that PBA can alleviate inflammation by reducing ER stress in endothelial cells and (2) that when ER stress is elevated, mitochondria are damaged51–53. As demonstrated by electron micrographs of the lacrimal glands, when mice were treated with the solvent-vehicle, mitochondria in the blood vessels were impaired. In contrast, this phenomenon was not observed in the lacrimal glands collected from the PBA-medicated mice. Thus, these findings indicate that PBA can protect blood vessels from cGVHD-caused ER stress and thereby suppress immune cell migration to tissues.

Mallory staining and immunoblot analysis of the fibrosis marker CTGF demonstrate that systemic fibrosis was subdued by PBA. Our literature search has revealed that epithelial to mesenchymal transition (EMT) correlates with fibrosis observed in human ocular cGVHD and that TXNIP is linked to EMT54,55. Hence, PBA is conceivably able to attenuate cGVHD-triggered systemic fibrosis, partly because it precludes EMT by lowering the expression of TXNIP. Furthermore, as indicated by ELISA, sera collected from the PBA-dosed mice displayed the lower levels of the inflammatory molecules MCP-1, TNF-α and IFN-γ in comparison to those obtained from their vehicle-dosed equivalents. CTGF is known to serve as an indicator for fibrosis56, and our immunoblot analysis of the cGVHD-susceptible organs indicates that PBA can prevent the cGVHD-elicited overexpression of CTGF. These results have underpinned our claim that reduction of ER stress can attenuate disabling symptoms caused by systemic cGVHD, and have encouraged us to conduct more painstaking investigation into the correlation between ER stress and the pathogenic process of cGVHD. As mentioned above, cGVHD causes extensive fibrosis in various organs. Although there is sparse information about the mechanisms of cGVHD-induced fibrosis, a previous report demonstrates that the murine lacrimal glands impaired by cGVHD have the increased number of activated fibroblasts and that they are associated with the progression of fibrosis52. Hence, we focused on fibroblasts in the lacrimal glands and scrutinized a correlation between cGVHD-induced ER stress and disordered fibroblasts. Our data suggest (1) that cGVHD-caused ER stress activates fibroblasts in a detrimental way and thereby triggers extensive fibrosis and (2) that PBA can prevent fibroblasts from dysfunctioning through alleviation of ER stress.

Once we gained novel insights into how ER stress affected the function of fibroblasts, our focus was turned to macrophages. A previous study demonstrates that senescent macrophages serve a causative role in the development of ocular cGVHD53. Other workers have shown (1) that ER stress promotes the polarization into M2 macrophages and (2) that M2 macrophages are implicated in fibrosis-related diseases57–59. These reports captured our interest and motivated us to scrutinize the relationship between cGVHD-induced ER stress and M2 macrophage differentiation. Judging from immunofluorescence images, the cGVHD-impaired murine lacrimal glands had macrophages expressing the ER stress marker CHOP, whereas it was not the case with the PBA-medicated murine lacrimal glands. These observations indicate that macrophages subjected to ER stress are linked to the progression of cGVHD. Furthermore, splenic macrophages from PBA- and vehicle-mediated mice were induced and subsequently analysed utilizing sophisticated methods. Both immunohistochemistry and immunoblot analysis demonstrated that the PBA-treated splenic macrophages showed the lower protein levels of ER stress markers compared to their vehicle-treated counterparts. Quantitative mRNA analysis suggests (1) that the mRNA levels of the M2 markers TGFB and IL-10 are enhanced in the splenic macrophages treated with the solvent-vehicle and (2) that the gene expression of the M1 markers IL-1β and IL-6 is increased in those treated with PBA. Hence, it is conceivable (1) that cGVHD-induced ER stress promotes macrophages to differentiate into an alternatively activated phenotype and (2) that PBA can mitigate cGVHD-induced fibrosis by reducing ER stress in macrophages and transforming them into a classically activated phenotype.

Collectively, considering the safety and affordability of the ER stress reducer PBA, the reduction of cGVHD-caused ER stress can be an innovative and robust strategy for the treatment of systemic cGVHD and open up new prospects to cure other immune-mediated diseases associated with ER stress.

Methods
Eight-week-old B10.D2 and BALB/c mice were purchased from Sankyo Laboratory, Inc. (Tokyo, Japan). All the scientific experiments on mice were performed according to the Animal Welfare Act at Keio University School of Medicine. Our protocols for experiments on animals were approved by the animal care and use committee at Keio University (Approval Number: 09152). We also complied with the ARRIVE guidelines60.

Bone marrow transplantation. Bone marrow transplantation (BMT) was conducted to furnish a murine model of cGVHD45. In the case where the donors were B10.D2 mice and the recipients were BALB/c mice, it was allogeneic BMT to produce a murine model of cGVHD. In contrast, BMT from BALB/c to BALB/c mice was syngeneic BMT, and therefore cGVHD did not occur in the transplant recipients. The recipient mice without cGVHD served as syngeneic control subjects. The recipients were irradiated with 700cGy prior to the BMT, and the lethal irradiation was preformed using a Gammacel 137 Cs source (Hitachi Medico, Ltd, Tokyo, Japan). A suspension containing $1 \times 10^7$ bone marrow cells and $2 \times 10^6$ spleen cells from the donors was administrated to each of the recipient mice via tail vein. The donor cells were suspended in RPMI 1640 (Life Technologies Japan Ltd, Tokyo, Japan).
Treatment of allogeneic BMT recipient mice with PBA. We performed BMT as described in the Methods section, and the allogeneic BMT recipient mice were divided into 2 groups. One group was treated with PBA (10 mg/kg) (Aldrich, St. Louis, MO), and the other was given the solvent-vehicle PBS (pH 7.4) by intraperitoneal injection. We administered PBA or the solvent-vehicle to the allogeneic BMT recipients once per day from Day 10 to Day 27 after BMT. They were sacrificed Day 28 after BMT. In this study, the following cGVHD-susceptible organs were analyzed: extra-orbital lacrimal glands, the proximal part of small intestine, dorsum skin, liver, salivary glands, lung, large intestine and eyes.

Culture of fibroblasts from murine lacrimal glands. Fibroblasts derived from the murine lacrimal glands were cultured using the well-established method reported by Yaguchi et al. The murine lacrimal glands were collected and subsequently cut into small pieces. The tissue fragments were incubated at 37 °C in DMEM (Life Technologies Japan Ltd, Tokyo, Japan) containing 5% of fetal bovine serum (FBS) (Sigma, St. Louis, MO) and 5% of antibiotics. The antibiotics were a 1:1 aqueous mixture of streptomycin sulfate (Meiji Seika Pharma Co., Ltd, Tokyo, Japan) and benzylpenicillin potassium (Meiji Seika). Fibroblasts started growing from the minced pieces after 3–4 days. The fibroblasts were cultured in DMEM with 5% of FBS and 5% of antibiotics, and used for experiments after 3–5 passages. Trypsin (Becton Dickinson, Franklin Lakes, NJ) was used to detach the fibroblasts from the culture dishes.

Culture of splenic macrophages. We cultured murine splenic macrophages according to the method of Alatery and Besta with slight modifications. Splenocytes suspended in RPMI with 5% of FBS were seeded in culture dishes and left at 37 °C overnight. The floating cells were then removed. The desired cells attached to the dishes were cultured in RPMI containing recombinant murine M-CSF (5 ng/mL) (Peprotech, Rocky Hill, NJ), 5% of FBS and 5% of antibiotics for 7 days. The induced macrophages were subsequently detached from the culture dishes utilizing accutase (Thermo Fisher Scientific, Waltham, MA) and used for experiments.

Immunostaining of cultured macrophages. The induced macrophages were placed in 8-well chamber slides (Fibronectin Culture Slide; Corning Inc., Corning, NY) and fixed with 10% neutral buffered formalin. They were then blocked with methanol containing 0.3% hydrogen peroxide at RT for 30 min and incubated with the primary antibodies CD68 (AbD Serotec) and CHOP (Santa Cruz) at 4 °C overnight. The sections were subsequently treated with goat anti-mouse IgG (H + L) secondary antibody, Alexa Fluor 568 conjugate (Molecular Probes, Eugene, OR) and 4′,6-diamidino-2-phenylindole (DAPI) (Life Technologies) at RT for 45 minutes and mounted with an anti-fading mounting medium (Dako). Fluorescence images were taken with an LSM confocal microscope (Carl Zeiss).

Quantitative polymerase chain reaction. Total RNA was extracted from extra-orbital lacrimal glands, the proximal part of small intestine, dorsum skin, liver, and cultured fibroblasts and macrophages using an miRNeasy mini kit (Qiagen, Valencia, CA), and the corresponding complementary DNA was synthesized utilizing a Rever Tra Ace qPCR RT Kit (Toyobo Co. Ltd, Osaka, Japan). The primers required to analyze the mRNA expression of the following genes by the use of TaqMan real-time polymerase chain reaction (PCR) were purchased from Applied Biosystems (Applied Systems Inc, Streetsville, Ontario, Canada): the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), glucose regulated protein 78 (GRP78), Interleukin-1, tumor growth factor-β (TGF-β). Quantitative real-time PCR was performed using the Step One Plus system (Applied Biosystems). The 2−ΔΔCT method was used to analyze the data obtained, and GAPDH was used as an internal standard to measure the expression of mRNA.

Statistical analysis. Statistical significance was determined by the use of unpaired Mann–Whitney U test. Differences are considered significant in the case of P < 0.05. The acquired data are presented as means ± SD.

References

**Acknowledgements**

This research was subsidized by the Japanese Ministry of Education, Science, Sports and Culture, #26462668. The assistance of Dr Toshihiro Nagai, Dr Tetsuya Yano Keio University School of Medicine is also gratefully appreciated.

**Author Contributions**

S.M., Y.O., K.T. conceived the study, S.M., Y.O. designed the study, S.M. performed the experiments. S.M., Y.O., C.K., F.U., Y.K., K.T. analyzed the data; S.M., Y.O., C.K., F.U., Y.K., K.T. approved the final version of this manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Mukai, S. et al. Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid. *Sci. Rep.* 7, 41939; doi: 10.1038/srep41939 (2017).

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017